SCHEMBL24252799

SCHEMBL24252799

COc1ccc(CNc2cnnc3cc(B(O)O)ccc23)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.47
APLNR P35414 1/20 0.43
DHFR P00374 1/20 0.41
NPC1 O15118 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41
CYP1A2 P05177 9/20 0.40
CYP3A4 P08684 9/20 0.40
CYP2C19 P33261 9/20 0.40
CYP2D6 P10635 8/20 0.40
TSHR P16473 7/20 0.40
HSD17B10 Q99714 5/20 0.40
LMNA P02545 5/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP2C9 P11712 7/20 0.40
CLK4 Q9HAZ1 5/20 0.40
ALDH1A1 P00352 4/20 0.40
USP2 O75604 3/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451531 1.00 KDM4C (0.47) KDM4CAPLNRDHFRNPC1PKM
SCHEMBL24252810 0.84 KDM4C (0.47) KDM4CAPLNRDHFRNPC1PKM
SCHEMBL30451812 0.84 KDM4C (0.47) KDM4CAPLNRDHFRNPC1PKM
SCHEMBL25299117 0.82 CYP1A2 (0.54) KDM4CAPLNRNPC1PKMRAB9A
Formic Acid SCHEMBL30451517 0.79 CYP1A2 (0.49) KDM4CAPLNRNPC1PKMRAB9A
SCHEMBL24252808 0.77 CYP1A2 (0.46) KDM4CDHFRCYP1A2CYP3A4CYP2C19
SCHEMBL30451317 0.77 CYP1A2 (0.46) KDM4CDHFRCYP1A2CYP3A4CYP2C19
SCHEMBL24252969 0.77 KDM4C (0.41) KDM4CAPLNRDHFRNPC1PKM
SCHEMBL30462772 0.77 KDM4C (0.41) KDM4CAPLNRDHFRNPC1PKM
SCHEMBL24252425 0.77 KDM4C (0.44) KDM4CAPLNRDHFRNPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885DHFR 1380/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885DHFR 1380/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885DHFR 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.